The fact that inflammation appears early in AMD pathology may explain why anti-inflammatory agents are beneficial as preventive or adjunctive therapies in combination with anti-VEGF therapy. Mast cells stimulate inflammation through the release of TNF-α, which in turn, recruits inflammatory cells including macrophages and neutrophils. Here, VEGFA is linked to age-related macular degeneration.